Peter J.M. Valk

25.6k citations

192 papers · 10.1k · 3 hit papers · h-index 50

Impact in

Hematology top 0.05%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 148
- Acute Myeloid Leukemia Research 132
- Chronic Myeloid Leukemia Treatments 28
Molecular Biology 93
- Protein Degradation and Inhibitors 24
- Epigenetics and DNA Methylation 23
- Histone Deacetylase Inhibitors Research 13

Co-authors: Bob Löwenberg (91 shared papers)Ruud Delwel (66 shared papers)Claudia Erpelinck-Verschueren (29 shared papers)H. Berna Beverloo (16 shared papers)Roel G.W. Verhaak (10 shared papers)Bas J. Wouters (15 shared papers)Mathijs A. Sanders (28 shared papers)Sanne Lugthart (10 shared papers)
Journals: Blood (65 papers)Haematologica (12 papers)British Journal of Haematology (8 papers)Blood Advances (8 papers)Leukemia (7 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Peter J.M. Valk

185 papers receiving 9.9k citations

Peter J.M. Valk's Hit Papers

align trajectories log scale

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome 2022 · 167 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2022 Blood
2010 Cancer Cell
2004 New England Journal of Medicine

Peers

Countries citing papers authored by Peter J.M. Valk

Since Specialization

Citations

This map shows the geographic impact of Peter J.M. Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J.M. Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J.M. Valk more than expected).

Fields of papers citing papers by Peter J.M. Valk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J.M. Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J.M. Valk. The network helps show where Peter J.M. Valk may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter J.M. Valk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter J.M. Valk Line = papers co-authored together Peter J.M. Valk links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 192 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia New England Journal of Medicine ·Peter J.M. Valk, Roel G.W. Verhaak, M. Antoinette Beijen, Claudia Erpelinck-Verschueren, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Judith M. Boer, H. Berna Beverloo, Michael Moorhouse, Peter J. van der Spek, Bob Löwenberg, Ruud Delwel Hit paper breakdown →	2004	999
2	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia Cancer Cell ·María E. Figueroa, Sanne Lugthart, Yushan Li, Claudia Erpelinck-Verschueren, Xutao Deng, Paul J. Christos, Elizabeth D. Schifano, James G. Booth, Wim van Putten, Lucy Skrabanek, Fabien Campagne, Madhu Mazumdar, John M. Greally, Peter J.M. Valk, Bob Löwenberg, Ruud Delwel, Ari Melnick Hit paper breakdown →	2010	581
3	Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance Blood ·Roel G.W. Verhaak, Chantal S. Goudswaard, Wim van Putten, Maarten Bijl, Mathijs A. Sanders, Wendy Hugens, André G. Uitterlinden, Claudia Erpelinck-Verschueren, Ruud Delwel, Bob Löwenberg, Peter J.M. Valk	2005	437
4	Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood ·Bas J. Wouters, Bob Löwenberg, Claudia Erpelinck-Verschueren, Wim L.J. van Putten, Peter J.M. Valk, Ruud Delwel	2009	384
5	MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood ·Mojca Jongen‐Lavrencic, Su Ming Sun, M K Dijkstra, Peter J.M. Valk, Bob Löwenberg	2008	321
6	Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value Blood ·Saman Abbas, Sanne Lugthart, François G. Kavelaars, Anita M. Schelen, Jasper Koenders, Annelieke Zeilemaker, Wim J. L. van Putten, Anita W. Rijneveld, Bob Löwenberg, Peter J.M. Valk	2010	286
7	Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity Blood ·Erdogan Taskesen, Lars Bullinger, Andrea Corbacioglu, Mathijs A. Sanders, Claudia Erpelinck-Verschueren, Bas J. Wouters, Sonja C. van der Poel-van de Luytgaarde, Frédérik Damm, Jürgen Krauter, Arnold Ganser, Richard F. Schlenk, Bob Löwenberg, Ruud Delwel, Hartmut Döhner, Peter J.M. Valk, Konstanze Döhner	2010	265
8	Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling Haematologica ·Roeland Verhaak, Bas J. Wouters, Claudia Erpelinck-Verschueren, Sakina Abbas, H. Berna Beverloo, Sanne Lugthart, Bob Löwenberg, R Delwel, Peter J.M. Valk	2008	247
9	Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias British Journal of Haematology ·Rory Care, Peter J.M. Valk, Anne Goodeve, Faisel M. Abuduhier, W. M. C. Geertsma-Kleinekoort, G. A. Wilson, Mamdooh Gari, I. R. Peake, Bob Löwenberg, John T. Reilly	2003	231
10	High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated Blood ·Sanne Lugthart, Ellen van Drunen, Yvette van Norden, Antoinette van Hoven, Claudia Erpelinck-Verschueren, Peter J.M. Valk, H. Berna Beverloo, Bob Löwenberg, Ruud Delwel	2008	215
11	Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival Genes & Development ·Hanno Hock, Eliza Meade, Sarah K. Medeiros, Jeffrey W. Schindler, Peter J.M. Valk, Yuko Fujiwara, Stuart H. Orkin	2004	205
12	NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern Blood ·Iris H.I.M. Hollink, Marry M. van den Heuvel‐Eibrink, Susan T.C.J.M. Arentsen-Peters, Marta Pratcorona, Saman Abbas, Jenny E. Kuipers, Janneke F. van Galen, H. Berna Beverloo, Edwin Sonneveld, Gertjan J.L. Kaspers, Jan Trka, André Baruchel, Martin Zimmermann, Ursula Creutzig, Dirk Reinhardt, Rob Pieters, Peter J.M. Valk, C. Michel Zwaan	2011	197
13	Tribbles homolog 2 inactivates C/EBPα and causes acute myelogenous leukemia Cancer Cell ·Karen Keeshan, Yiping He, Bas J. Wouters, Olga Shestova, Lanwei Xu, Hong Sai, Carlos G. Rodríguez, Ivan Maillard, John W. Tobias, Peter J.M. Valk, Martin Carroll, Jon C. Aster, Ruud Delwel, Warren S. Pear	2006	195
14	High EVI1 Expression Predicts Outcome in Younger Adult Patients With Acute Myeloid Leukemia and Is Associated With Distinct Cytogenetic Abnormalities Journal of Clinical Oncology ·Stefan Gröschel, Sanne Lugthart, Richard F. Schlenk, Peter J.M. Valk, Karina Eiwen, Chantal S. Goudswaard, Wim J. L. van Putten, Sabine Käyser, Leo F. Verdonck, Michael Lübbert, Gert-Jan Ossenkoppele, Ulrich Germing, Ingo G.H. Schmidt‐Wolf, Brigitte Schlegelberger, Jürgen Krauter, Arnold Ganser, Hartmut Döhner, Bob Löwenberg, Konstanze Döhner, Ruud Delwel	2010	189
15	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia Blood ·Ana Flávia Tibúrcio Ribeiro, Marta Pratcorona, Claudia Erpelinck-Verschueren, Veronika Ročková, Mathijs A. Sanders, Saman Abbas, María E. Figueroa, Annelieke Zeilemaker, Ari Melnick, Bob Löwenberg, Peter J.M. Valk, Ruud Delwel	2012	186
16	Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML The Hematology Journal ·Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Claudia Erpelinck-Verschueren, Joost M. Meijer, Susanna van Oosterhoud, Wim L.J. van Putten, Peter J.M. Valk, H. Berna Beverloo, Daniel G. Tenen, Bob Löwenberg, Ruud Delwel	2003	183
17	Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome Blood ·Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja Gradowska, Bart J. Biemond, Dimitri Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen‐Lavrencic, Peter J.M. Valk Hit paper breakdown →	2022	167
18	MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome Cancer Cell ·Vaia Stavropoulou, Susanne Kaspar, Laurent Brault, Mathijs A. Sanders, Sabine Juge, Stefano Morettini, Alexandar Tzankov, Michelina Iacovino, I‐Jun Lau, Thomas A. Milne, Hélène Royo, Michael Kyba, Peter J.M. Valk, Antoine H.F.M. Peters, Juerg Schwaller	2016	152
19	Cell of origin determines clinically relevant subtypes of MLL-rearranged AML Leukemia ·Andrei V. Krivtsov, María E. Figueroa, Amit Sinha, Matthew C. Stubbs, Zhaohui Feng, Peter J.M. Valk, Ruud Delwel, Konstanze Döhner, Lars Bullinger, Andrew L. Kung, Ari Melnick, Scott A. Armstrong	2012	152
20	Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1 Blood ·Bas J. Wouters, Meritxell Alberich-Jordà, Karen Keeshan, Irene Louwers, Claudia Erpelinck-Verschueren, Dennis Tielemans, Anton W. Langerak, Yiping He, Yumi Yashiro–Ohtani, Pu Zhang, Christopher J. Hetherington, Roel G.W. Verhaak, Peter J.M. Valk, Bob Löwenberg, Daniel G. Tenen, Warren S. Pear, Ruud Delwel	2007	142

About Peter J.M. Valk

Peter J.M. Valk is a scholar working on Hematology, Molecular Biology, Genetics, Cancer Research and Oncology, having authored 192 papers that have together received 10.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (132 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (29 papers), Chronic Myeloid Leukemia Treatments (28 papers), Protein Degradation and Inhibitors (24 papers), Epigenetics and DNA Methylation (23 papers), Cancer Genomics and Diagnostics (20 papers), Acute Lymphoblastic Leukemia research (13 papers) and Histone Deacetylase Inhibitors Research (13 papers). The work is most often cited by research in Hematology (6.1k citations), Genetics (1.8k citations), Cancer Research (1.4k citations), Molecular Biology (5.3k citations) and Immunology (1.0k citations). Peter J.M. Valk has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Bob Löwenberg, Ruud Delwel, Claudia Erpelinck-Verschueren, H. Berna Beverloo, Roel G.W. Verhaak, Bas J. Wouters, Mathijs A. Sanders, Sanne Lugthart, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani and Peter J. van der Spek. Their work appears in journals such as Blood, Haematologica, British Journal of Haematology, Blood Advances and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Peter J.M. Valk

Impact in

Papers in i

In The Last Decade

Peter J.M. Valk

Peter J.M. Valk's Hit Papers

Peers

Countries citing papers authored by Peter J.M. Valk

Fields of papers citing papers by Peter J.M. Valk

All Works

About Peter J.M. Valk

Explore authors with similar magnitude of impact

Papers in